US Food and Drug Administration approvals continue to lag behind the European Medicine Agency (EMA), particularly with the US government shutdown; 2013 is shaping up as a very poor year for first-in-class drug approvals. EMA approved the first biosimilar monoclonal antibody; Biogen, Pharmacyclics, Clinuvel, Actelion and Celgene all await final regulatory decisions.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline 3Q13. Nat Biotechnol 31, 956 (2013). https://doi.org/10.1038/nbt.2746
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2746